Ropinirole
Treatment for Restless Legs Syndrome
Typical Dosage: 0.25-4 mg daily
Effectiveness
78%
Safety Score
58%
Clinical Trials
25
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
0.25-4 mg daily
Time to Effect
1-3 days
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180
Monitoring:$300
Side Effect Mgmt:$50
Total Annual:$530
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$10,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$757
Cost per Remission
$2,120
Ropinirole Outcomes
for Restless Legs Syndrome
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+70%
Remission Rate
+25%
Common Side Effects
Nausea
+15%
Somnolence
+15%
Dizziness
+10%
Augmentation (long-term)
+30%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
19 completed trials for Ropinirole in Restless Legs Syndrome
A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome
NCT00363857COMPLETEDPHASE3
360 participants
INTERVENTIONAL
Alabaster, United States +48 more
Started: Aug 1, 2003
REQUIP RLS Post Marketing Surveillance
NCT01327339COMPLETED
755 participants
OBSERVATIONAL
Started: Apr 1, 2006
Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)
NCT00256854COMPLETEDPHASE3
135 participants
INTERVENTIONAL
Laguna Hills, United States +29 more
Started: Nov 14, 2005
A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)
NCT00225862COMPLETEDPHASE3
140 participants
INTERVENTIONAL
Alabaster, United States +36 more
Started: Jan 1, 2005
Long-term Study Of Ropinirole In Restless Legs Syndrome
NCT00329602COMPLETEDPHASE4
404 participants
INTERVENTIONAL
Camperdown, Australia +38 more
Started: Mar 1, 2006
Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food
NCT00419692COMPLETEDPHASE1
32 participants
INTERVENTIONAL
Berlin, Germany +1 more
Started: Aug 24, 2006
12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
NCT00373542COMPLETEDPHASE4
39 participants
INTERVENTIONAL
Jasper, United States +44 more
Started: Oct 1, 2006
Ropinirole Tablets In Young Patients With Restless Legs Syndrome
NCT00140712COMPLETEDPHASE1
9 participants
INTERVENTIONAL
Washington D.C., United States +8 more
Started: Jun 10, 2005
Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome
NCT00355641COMPLETEDPHASE3
450 participants
INTERVENTIONAL
Alabaster, United States +64 more
Started: Oct 1, 2005
Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)
NCT00367822COMPLETEDPHASE3
300 participants
INTERVENTIONAL
Nuremberg, Germany
Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome
NCT00530790COMPLETEDPHASE2
35 participants
INTERVENTIONAL
Fukuoka, Japan +10 more
Started: Aug 23, 2007
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
NCT00314860COMPLETEDPHASE3
568 participants
INTERVENTIONAL
Birmingham, United States +90 more
Started: Feb 1, 2006
Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome
NCT00197080COMPLETEDPHASE3
380 participants
INTERVENTIONAL
Alabaster, United States +69 more
Started: Jun 1, 2005
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
NCT00357097COMPLETEDPHASE3
240 participants
INTERVENTIONAL
Ellwangen, Germany +49 more
Started: Jun 1, 2006
SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole
NCT00344994COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Augusta, United States
Started: May 1, 2006
DIalysis Symptom COntrol-Restless Legs Syndrome Trial
NCT03806530COMPLETEDPHASE3
52 participants
INTERVENTIONAL
Halifax, Canada +2 more
Started: May 1, 2019
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
NCT00422994COMPLETEDPHASE1
48 participants
INTERVENTIONAL
Minneapolis, United States +1 more
Started: Apr 1, 2006
Effect of Ropinirole on Spinal Cord Reflexes and Restless Legs Syndrome
NCT00051961COMPLETED
90 participants
OBSERVATIONAL
Bethesda, United States
Started: Jan 14, 2003
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions
NCT00674310COMPLETEDNA
29 participants
INTERVENTIONAL
Started: Feb 1, 2004
Showing 20 of 25 total trials